Tapinarof 1%乳膏每日一次治疗斑块状银屑病的患者报告结局:PSOARING 3试验
PSOARING 3是一项开放标签扩展研究,纳入完成两项12周III期试验的轻至重度斑块状银屑病成人患者,评估tapinarof 1%乳膏每日一次长期治疗的健康相关生活质量和患者满意度。结果显示DLQI评分改善并维持,第40周时68.0%患者DLQI为0或1,多数患者对疗效、应用便利性和化妆品优雅性表示满意。
要点
- 第40周时68.0%患者DLQI为0或1,表明银屑病对健康相关生活质量无影响。
- 62.9%-85.8%患者对tapinarof的信心和疗效满意度表示强烈同意或同意。
- 79.9%-96.3%患者对应用便利性和化妆品优雅性表示满意。
核心结论
- 持续和持久的健康相关生活质量改善、高患者满意度和对tapinarof 1%乳膏的积极认知得到证实。
研究设计与样本
- 开放标签扩展研究,纳入完成两项12周III期试验的轻至重度斑块状银屑病成人患者,基于医生全球评估进入40周开放标签tapinarof治疗,随访4周。
- 共有763例(91.6%)合格患者入组,78.5%完成患者满意度问卷。
主要发现
- DLQI评分改善并维持。
- 第40周时68.0%患者DLQI为0或1,表明银屑病对健康相关生活质量无影响。
- 大多数患者对所有患者满意度问卷问题表示强烈同意或同意:对tapinarof的信心和疗效满意度为62.9%-85.8%,应用便利性和化妆品优雅性为79.9%-96.3%,对tapinarof与既往银屑病治疗的偏好为55.3%-81.7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 开放标签。
- 无对照。
- 可能不能推广至所有类型的银屑病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tapinarof cream 1% once daily demonstrated significant efficacy versus vehicle and was well tolerated in two 12-week, phase 3 pivotal trials in adults with mild-to-severe plaque psoriasis. OBJECTIVE: To assess long-term, health-related quality of life and patient satisfaction with tapinarof. METHODS: Patients completing the 12-week trials were eligible for 40 weeks of open-label tapinarof based on Physician Global Assessment score in PSOARING 3, with a 4-week follow-up. Dermatology Life Quality Index was assessed at every visit; Patient Satisfaction Questionnaire responses were assessed at week 40 or early termination. RESULTS: Seven hundred sixty-three (91.6%) eligible patients enrolled; 78.5% completed the Patient Satisfaction Questionnaire. DLQI scores improved and were maintained. By week 40, 68.0% of patients had a DLQI of 0 or 1, indicating no impact of psoriasis on health-related quality of life. Most patients strongly agreed or agreed with all Patient Satisfaction Questionnaire questions assessing confidence in tapinarof and satisfaction with efficacy (62.9%-85.8%), application ease and cosmetic elegance (79.9%-96.3%), and preference for tapinarof versus prior psoriasis therapies (55.3%-81.7%). LIMITATIONS: Open-label; no control; may not be generalizable to all forms of psoriasis. CONCLUSIONS: Continued and durable improvements in health-related quality of life, high rates of patient satisfaction, and positive perceptions of tapinarof cream were demonstrated.
引用
- Bagel J, Gold LS, Del Rosso J, et al. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial. J Am Acad Dermatol. 2023. PMID: 37172733. doi:10.1016/j.jaad.2023.04.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。